On Monday, global monkeypox virus cases topped 1,000, urging the Centers for Disease Control and Prevention to raise its alert to Level 2 and warn travelers to take extra precautions.
In a bid to stay ahead of the virus, Franklin Lakes-based medical company BD (Becton, Dickinson and Co.) announced on June 8 that it was collaborating with Spain-based CerTest Biotec to develop a test molecular diagnostics for monkeypox.
This collaboration will enable the BD MAX System, a fully integrated and automated platform that provides test results for up to 24 samples across multiple syndromes in less than three hours, to validate the CerTest Viasure Monkeypox CE/IVD molecular test.
According to the CDC, monkeypox is a rare disease that can be spread “by contact with the skin lesions or bodily fluids of infected animals or humans (alive or dead), including respiratory droplets, or by contact with materials contaminated with the virus”. Symptoms include fever, headache, muscle aches, swollen lymph nodes, and a rash.
“Enabling labs to respond quickly to unexpected challenges is the type of evolving healthcare situations the BD MAX open-system reagent suite is designed for,” said Nikos Pavlidis, vice president of molecular diagnostics at BD. , in a press release. “Through our collaboration with CerTest and their ability to quickly transfer tests to the BD MAX System, we will provide BD MAX System users worldwide with access to a test for the confirmation of monkeypox.
The BD MAX System is also used to test for respiratory infections, sexually transmitted infections, gastrointestinal infections, and women’s health diagnostics.